Medicare Program; Approval of Application by the Community Health Accreditation Partner for Initial CMS-Approval of Its Home Infusion Therapy Accreditation Program, 60469-60471 [2020-21147]
Download as PDF
Federal Register / Vol. 85, No. 187 / Friday, September 25, 2020 / Notices
shares of Security State Bank Holding
Company, Fargo, North Dakota, and
thereby indirectly acquire additional
voting shares of Bank Forward,
Hannaford, North Dakota.
B. Federal Reserve Bank of Kansas
City (Dennis Denney, Assistant Vice
President) 1 Memorial Drive, Kansas
City, Missouri 64198–0001:
1. Bern Bancshares, Inc., Bern,
Kansas; to acquire up to 7 percent of the
voting shares of UBT Bancshares, Inc.,
and thereby indirectly acquire voting
shares of United Bank & Trust, both of
Marysville, Kansas.
Board of Governors of the Federal Reserve
System, September 22, 2020.
Yao-Chin Chao,
Assistant Secretary of the Board.
[FR Doc. 2020–21213 Filed 9–24–20; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–R–153]
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Medicare &
Medicaid Services (CMS) is announcing
an opportunity for the public to
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995
(PRA), federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension or reinstatement of an existing
collection of information, and to allow
a second opportunity for public
comment on the notice. Interested
persons are invited to send comments
regarding the burden estimate or any
other aspect of this collection of
information, including the necessity and
utility of the proposed information
collection for the proper performance of
the agency’s functions, the accuracy of
the estimated burden, ways to enhance
the quality, utility, and clarity of the
information to be collected, and the use
of automated collection techniques or
other forms of information technology to
minimize the information collection
burden.
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:25 Sep 24, 2020
Jkt 250001
Comments on the collection(s) of
information must be received by the
OMB desk officer by October 26, 2020.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
To obtain copies of a supporting
statement and any related forms for the
proposed collection(s) summarized in
this notice, you may make your request
using one of following:
1. Access CMS’ website address at
website address at https://www.cms.gov/
Regulations-and-Guidance/Legislation/
PaperworkReductionActof1995/PRAListing.html.
2. Call the Reports Clearance Office at
(410) 786–1326.
FOR FURTHER INFORMATION CONTACT:
William Parham at (410) 786–4669.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. The term ‘‘collection of
information’’ is defined in 44 U.S.C.
3502(3) and 5 CFR 1320.3(c) and
includes agency requests or
requirements that members of the public
submit reports, keep records, or provide
information to a third party. Section
3506(c)(2)(A) of the PRA (44 U.S.C.
3506(c)(2)(A)) requires federal agencies
to publish a 30-day notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension or
reinstatement of an existing collection
of information, before submitting the
collection to OMB for approval. To
comply with this requirement, CMS is
publishing this notice that summarizes
the following proposed collection(s) of
information for public comment:
1. Type of Information Collection
Request: Revision of a currently
approved collection; Title of
Information Collection: Medicaid Drug
Use Review (DUR) Program; Use: States
must provide for a review of drug
therapy before each prescription is filled
or delivered to a Medicaid patient. This
review includes screening for potential
drug therapy problems due to
therapeutic duplication, drug-disease
contraindications, drug-drug
interactions, incorrect drug dosage or
duration of drug treatment, drug-allergy
interactions, and clinical abuse/misuse.
DATES:
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
60469
Pharmacists must make a reasonable
effort to obtain, record, and maintain
Medicaid patient profiles. These profiles
must reflect at least the patient’s name,
address, telephone number, date of
birth/age, gender, history, e.g., allergies,
drug reactions, list of medications, and
pharmacist’s comments relevant to the
individual’s drug therapy.
The States must conduct RetroDUR
which provides for the ongoing periodic
examination of claims data and other
records in order to identify patterns of
fraud, abuse, inappropriate or medically
unnecessary care. Patterns or trends of
drug therapy problems are identified
and reviewed to determine the need for
intervention activity with pharmacists
and/or physicians. States may conduct
interventions via telephone,
correspondence, or face-to-face contact.
Annual reports are submitted to CMS
for the purposes of monitoring
compliance and evaluating the progress
of States’ DUR programs. The
information submitted by States is
reviewed and results are compiled by
CMS in a format intended to provide
information, comparisons, and trends
related to States’ experiences with DUR.
States benefit from the information and
may enhance their programs each year
based on State reported innovative
practices that are compiled by CMS
from the DUR annual reports. Form
Number: CMS–R–153 (OMB control
number: 0938–0659); Frequency: Yearly,
quarterly, and occasionally; Affected
Public: State, Local, or Tribal
Governments; Number of Respondents:
51; Total Annual Responses: 663; Total
Annual Hours: 41,004. (For policy
questions regarding this collection
contact Mike Forman at 410–786–2666.)
Dated: September 22, 2020.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office
of Strategic Operations and Regulatory
Affairs.
[FR Doc. 2020–21181 Filed 9–24–20; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–3393–FN]
Medicare Program; Approval of
Application by the Community Health
Accreditation Partner for Initial CMSApproval of Its Home Infusion Therapy
Accreditation Program
Centers for Medicare and
Medicaid Services, HHS.
AGENCY:
E:\FR\FM\25SEN1.SGM
25SEN1
60470
ACTION:
Federal Register / Vol. 85, No. 187 / Friday, September 25, 2020 / Notices
Final notice.
This final notice announces
our decision to approve the Community
Health Accreditation Partner (CHAP) for
initial recognition as a national
accrediting organization for home
infusion therapy suppliers that wish to
participate in the Medicare program. A
home infusion therapy supplier that
participates must meet the Medicare
conditions for coverage.
DATES: The approval announced in this
final notice is effective September 25,
2020 through September 25, 2024.
FOR FURTHER INFORMATION CONTACT:
Christina Mister-Ward, (410) 786–
2441.
Shannon Freeland, (410) 786–4348.
Lillian Williams, (410) 786–8636.
SUPPLEMENTARY INFORMATION:
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
I. Background
Home Infusion therapy (HIT) is a
treatment option for Medicare
beneficiaries with a wide range of acute
and chronic conditions. Section 5012 of
the 21st Century Cures Act (Pub. L. 114–
255, enacted on December 13, 2016)
added sections 1861(iii) and 1834(u) to
the Social Security Act (the Act),
establishing a new Medicare benefit for
HIT services. Section 1861(iii)(1) of the
Act defines HIT as professional services,
including nursing services; training and
education not otherwise covered under
the Durable Medical Equipment (DME)
benefit; remote monitoring; and other
monitoring services. Home infusion
therapy must be furnished by a qualified
HIT supplier and furnished in the
individual’s home. The individual must:
• Be under the care of an applicable
provider (that is, physician, nurse
practitioner, or physician assistant); and
• Have a plan of care established and
periodically reviewed by a physician in
coordination with the furnishing of
home infusion drugs under Part B, that
prescribes the type, amount, and
duration of infusion therapy services
that are to be furnished.
Section 1861(iii)(3)(D)(i)(III) of the Act
requires that a qualified HIT supplier be
accredited by an accrediting
organization (AO) designated by the
Secretary in accordance with section
1834(u)(5) of the Act. Section
1834(u)(5)(A) of the Act identifies
factors for designating AOs and in
reviewing and modifying the list of
designated AOs. These statutory factors
are as follows:
• The ability of the organization to
conduct timely reviews of accreditation
applications.
• The ability of the organization take
into account the capacities of suppliers
VerDate Sep<11>2014
18:25 Sep 24, 2020
Jkt 250001
located in a rural area (as defined in
section 1886(d)(2)(D) of the Act).
• Whether the organization has
established reasonable fees to be
charged to suppliers applying for
accreditation.
• Such other factors as the Secretary
determines appropriate.
Section 1834(u)(5)(B) of the Act
requires the Secretary to designate AOs
to accredit HIT suppliers furnishing HIT
not later than January 1, 2021. Section
1861(iii)(3)(D) of the Act defines
‘‘qualified home infusion therapy
suppliers’’ as being accredited by a
CMS-approved AO.
In the March 1, 2019 Federal Register,
we published a solicitation notice
entitled, ‘‘Medicare Program;
Solicitation of Independent Accrediting
Organizations To Participate in the
Home Infusion Therapy Supplier
Accreditation Program’’ (84 FR 7057).
This notice informed national AOs that
accredit HIT suppliers of an opportunity
to submit applications to participate in
the HIT supplier accreditation program.
Complete applications will be
considered for the January 1, 2021
designation deadline if received by
February 1, 2020.
Regulations for the approval and
oversight of AOs for HIT organizations
are located at 42 CFR part 488, subpart
L. The requirements for HIT suppliers
are located at 42 CFR part 486, subpart
I.
II. Approval of Accreditation
Organizations
Section 1834(u)(5) of the Act and the
regulations at § 488.1010 require that
our findings concerning review and
approval of a national AO’s
requirements consider, among other
factors, the applying AO’s requirements
for accreditation; survey procedures;
resources for conducting required
surveys; capacity to furnish information
for use in enforcement activities;
monitoring procedures for provider
entities found not in compliance with
the conditions or requirements; and
ability to provide CMS with the
necessary data.
Section 488.1020(a) requires that we
publish, after receipt of an
organization’s complete application, a
notice identifying the national
accrediting body making the request,
describing the nature of the request, and
providing at least a 30-day public
comment period. In accordance with
§ 488.1010(d), we have 210 days from
the receipt of a complete application to
approve or deny the application.
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
III. Provisions of the Proposed Notice
In the April 27, 2020 Federal Register
(85 FR 23364), we published a proposed
notice announcing the Community
Health Accreditation Partner’s (CHAP’s)
request for initial approval of its
Medicare HIT accreditation program. In
that proposed notice, we detailed our
evaluation criteria. Under section
1834(u)(5) the Act and in our
regulations at § 488.1010, we conducted
a review of CHAP’s Medicare HIT
accreditation application in accordance
with the criteria specified by our
regulations, which included, but are not
limited to the following:
• An administrative review of
CHAP’s: (1) Corporate policies; (2)
financial and human resources available
to accomplish the proposed surveys; (3)
procedures for training, monitoring, and
evaluation of its home infusion therapy
surveyors; (4) ability to investigate and
respond appropriately to complaints
against accredited home infusion
therapies; and (5) survey review and
decision-making process for
accreditation.
• The ability for CHAP to conduct
timely review of accreditation
applications.
• The ability of CHAP to take into
account the capacities of suppliers
located in a rural area.
• The comparison of CHAP’s
Medicare HIT accreditation program
standards to our current Medicare home
infusion therapy conditions for coverage
(CfCs).
• CHAP’s survey process to
determine the following:
++ The composition of the survey
team, surveyor qualifications, and
CHAP’s ability to provide continuing
surveyor training.
++ CHAP’s processes, including
periodic resurvey and the ability to
investigate and respond appropriately to
complaints against accredited home
infusion therapies.
++ Evaluate CHAP’s procedures for
monitoring home infusion therapies it
has found to be out of compliance with
CHAP’s program requirements.
++ Assess CHAP’s ability to report
deficiencies to the surveyed home
infusion therapy and respond to the
home infusion therapy’s plan of
correction in a timely manner.
++ Establish CHAP’s ability to
provide CMS with electronic data and
reports necessary for effective validation
and assessment of the organization’s
survey process.
++ Determine the adequacy of CHAP’s
staff and other resources.
++ Confirm CHAP’s ability to provide
adequate funding for performing
required surveys.
E:\FR\FM\25SEN1.SGM
25SEN1
Federal Register / Vol. 85, No. 187 / Friday, September 25, 2020 / Notices
++ Confirm CHAP’s policies with
respect to surveys being unannounced.
++ Review CHAP’s policies and
procedures to avoid conflicts of interest,
including the appearance of conflicts of
interest, involving individuals who
conduct surveys or participate in
accreditation decisions.
++ Obtain CHAP’s agreement to
provide CMS with a copy of the most
current accreditation survey together
with any other information related to
the survey as we may require, including
corrective action plans.
The April 27, 2020 proposed notice
also solicited public comments
regarding whether CHAP’s requirements
met or exceeded the Medicare CfCs for
home infusion therapy. No comments
were received in response to our
proposed notice.
IV. Provisions of the Final Notice
khammond on DSKJM1Z7X2PROD with NOTICES
A. Differences Between CHAP’s
Standards and Requirements for
Accreditation and Medicare Conditions
and Survey Requirements
We compared CHAP’s HIT
accreditation requirements and survey
process with the Medicare CfCs of part
486, subpart I and the survey and
certification process requirements of
part 488, subpart L. Our review and
evaluation of CHAP’s HIT application,
which was conducted as described in
section III. of this final notice, yielded
the following areas where, as of the date
of this notice, CHAP has completed
revising its standards and certification
processes in order to meet the condition
at:
• Section 486.520(b), to address the
requirement of the plan of care must be
established by a physician prescribing
the type, amount and duration for home
infusion therapy.
• Section 486.525(a), to include the
required language ‘‘plan of care’’.
• Section 488.1010(a)(6)(iv), to revise
CHAP’s procedures for survey reviews.
B. Term of Approval
As authorized under § 488.1040(a), we
reserve the right to conduct onsite
observations of accrediting organization
operations at any time as part of the
ongoing review and continuing
oversight of an accrediting
organization’s performance. Based on
the review and observations described
in section III. of this final notice, we
have determined that CHAP’s
requirements for HIT meet or exceed our
requirements. Therefore, we approve
CHAP as a national accreditation
organization for HITs that request
participation in the Medicare program,
effective September 25, 2020 through
September 25, 2024.
VerDate Sep<11>2014
18:25 Sep 24, 2020
Jkt 250001
V. Collection of Information
Requirements
This document does not impose
information collection and
requirements, that is, reporting,
recordkeeping or third party disclosure
requirements. Consequently, there is no
need for review by the Office of
Management and Budget under the
authority of the Paperwork Reduction
Act of 1995 (44 U.S.C. Chapter 35).
The Administrator of the Centers for
Medicare & Medicaid Services (CMS),
Seema Verma, having reviewed and
approved this document, authorizes
Lynette Wilson, who is the Federal
Register Liaison, to electronically sign
this document for purposes of
publication in the Federal Register.
Dated: September 21, 2020.
Lynette Wilson,
Federal Register Liaison, Centers for Medicare
& Medicaid.
[FR Doc. 2020–21147 Filed 9–24–20; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2019–D–3805]
The Accreditation Scheme for
Conformity Assessment Pilot Program;
Guidances for Industry, Accreditation
Bodies, Testing Laboratories, and
Food and Drug Administration Staff;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of three
final guidance documents for the
Accreditation Scheme for Conformity
Assessment Pilot Program—specifically,
‘‘The Accreditation Scheme for
Conformity Assessment (ASCA) Pilot
Program; Guidance for Industry,
Accreditation Bodies, Testing
Laboratories, and FDA Staff’’; ‘‘Basic
Safety and Essential Performance of
Medical Electrical Equipment, Medical
Electrical Systems, and Laboratory
Medical Equipment—Standards Specific
Information for the Accreditation
Scheme for Conformity Assessment
(ASCA) Pilot Program: Guidance for
Industry, Accreditation Bodies, Testing
Laboratories, and FDA Staff’’; and
‘‘Biocompatibility Testing of Medical
Devices—Standards Specific
Information for the Accreditation
Scheme for Conformity Assessment
SUMMARY:
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
60471
(ASCA) Pilot Program: Guidance for
Industry, Accreditation Bodies, Testing
Laboratories, and FDA Staff.’’ These
guidances describe the goals, scope,
procedures, and framework for the
voluntary ASCA Pilot program, and
provide information about two groups of
consensus standards within the scope of
the pilot program.
DATES: The announcement of these
guidances is published in the Federal
Register on September 25, 2020.
ADDRESSES: You may submit either
electronic or written comments on
Agency guidances at any time as
follows:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2019–D–3805 for ‘‘The Accreditation
Scheme for Conformity Assessment
E:\FR\FM\25SEN1.SGM
25SEN1
Agencies
[Federal Register Volume 85, Number 187 (Friday, September 25, 2020)]
[Notices]
[Pages 60469-60471]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-21147]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS-3393-FN]
Medicare Program; Approval of Application by the Community Health
Accreditation Partner for Initial CMS-Approval of Its Home Infusion
Therapy Accreditation Program
AGENCY: Centers for Medicare and Medicaid Services, HHS.
[[Page 60470]]
ACTION: Final notice.
-----------------------------------------------------------------------
SUMMARY: This final notice announces our decision to approve the
Community Health Accreditation Partner (CHAP) for initial recognition
as a national accrediting organization for home infusion therapy
suppliers that wish to participate in the Medicare program. A home
infusion therapy supplier that participates must meet the Medicare
conditions for coverage.
DATES: The approval announced in this final notice is effective
September 25, 2020 through September 25, 2024.
FOR FURTHER INFORMATION CONTACT:
Christina Mister-Ward, (410) 786-2441.
Shannon Freeland, (410) 786-4348.
Lillian Williams, (410) 786-8636.
SUPPLEMENTARY INFORMATION:
I. Background
Home Infusion therapy (HIT) is a treatment option for Medicare
beneficiaries with a wide range of acute and chronic conditions.
Section 5012 of the 21st Century Cures Act (Pub. L. 114-255, enacted on
December 13, 2016) added sections 1861(iii) and 1834(u) to the Social
Security Act (the Act), establishing a new Medicare benefit for HIT
services. Section 1861(iii)(1) of the Act defines HIT as professional
services, including nursing services; training and education not
otherwise covered under the Durable Medical Equipment (DME) benefit;
remote monitoring; and other monitoring services. Home infusion therapy
must be furnished by a qualified HIT supplier and furnished in the
individual's home. The individual must:
Be under the care of an applicable provider (that is,
physician, nurse practitioner, or physician assistant); and
Have a plan of care established and periodically reviewed
by a physician in coordination with the furnishing of home infusion
drugs under Part B, that prescribes the type, amount, and duration of
infusion therapy services that are to be furnished.
Section 1861(iii)(3)(D)(i)(III) of the Act requires that a
qualified HIT supplier be accredited by an accrediting organization
(AO) designated by the Secretary in accordance with section 1834(u)(5)
of the Act. Section 1834(u)(5)(A) of the Act identifies factors for
designating AOs and in reviewing and modifying the list of designated
AOs. These statutory factors are as follows:
The ability of the organization to conduct timely reviews
of accreditation applications.
The ability of the organization take into account the
capacities of suppliers located in a rural area (as defined in section
1886(d)(2)(D) of the Act).
Whether the organization has established reasonable fees
to be charged to suppliers applying for accreditation.
Such other factors as the Secretary determines
appropriate.
Section 1834(u)(5)(B) of the Act requires the Secretary to
designate AOs to accredit HIT suppliers furnishing HIT not later than
January 1, 2021. Section 1861(iii)(3)(D) of the Act defines ``qualified
home infusion therapy suppliers'' as being accredited by a CMS-approved
AO.
In the March 1, 2019 Federal Register, we published a solicitation
notice entitled, ``Medicare Program; Solicitation of Independent
Accrediting Organizations To Participate in the Home Infusion Therapy
Supplier Accreditation Program'' (84 FR 7057). This notice informed
national AOs that accredit HIT suppliers of an opportunity to submit
applications to participate in the HIT supplier accreditation program.
Complete applications will be considered for the January 1, 2021
designation deadline if received by February 1, 2020.
Regulations for the approval and oversight of AOs for HIT
organizations are located at 42 CFR part 488, subpart L. The
requirements for HIT suppliers are located at 42 CFR part 486, subpart
I.
II. Approval of Accreditation Organizations
Section 1834(u)(5) of the Act and the regulations at Sec. 488.1010
require that our findings concerning review and approval of a national
AO's requirements consider, among other factors, the applying AO's
requirements for accreditation; survey procedures; resources for
conducting required surveys; capacity to furnish information for use in
enforcement activities; monitoring procedures for provider entities
found not in compliance with the conditions or requirements; and
ability to provide CMS with the necessary data.
Section 488.1020(a) requires that we publish, after receipt of an
organization's complete application, a notice identifying the national
accrediting body making the request, describing the nature of the
request, and providing at least a 30-day public comment period. In
accordance with Sec. 488.1010(d), we have 210 days from the receipt of
a complete application to approve or deny the application.
III. Provisions of the Proposed Notice
In the April 27, 2020 Federal Register (85 FR 23364), we published
a proposed notice announcing the Community Health Accreditation
Partner's (CHAP's) request for initial approval of its Medicare HIT
accreditation program. In that proposed notice, we detailed our
evaluation criteria. Under section 1834(u)(5) the Act and in our
regulations at Sec. 488.1010, we conducted a review of CHAP's Medicare
HIT accreditation application in accordance with the criteria specified
by our regulations, which included, but are not limited to the
following:
An administrative review of CHAP's: (1) Corporate
policies; (2) financial and human resources available to accomplish the
proposed surveys; (3) procedures for training, monitoring, and
evaluation of its home infusion therapy surveyors; (4) ability to
investigate and respond appropriately to complaints against accredited
home infusion therapies; and (5) survey review and decision-making
process for accreditation.
The ability for CHAP to conduct timely review of
accreditation applications.
The ability of CHAP to take into account the capacities of
suppliers located in a rural area.
The comparison of CHAP's Medicare HIT accreditation
program standards to our current Medicare home infusion therapy
conditions for coverage (CfCs).
CHAP's survey process to determine the following:
++ The composition of the survey team, surveyor qualifications, and
CHAP's ability to provide continuing surveyor training.
++ CHAP's processes, including periodic resurvey and the ability to
investigate and respond appropriately to complaints against accredited
home infusion therapies.
++ Evaluate CHAP's procedures for monitoring home infusion
therapies it has found to be out of compliance with CHAP's program
requirements.
++ Assess CHAP's ability to report deficiencies to the surveyed
home infusion therapy and respond to the home infusion therapy's plan
of correction in a timely manner.
++ Establish CHAP's ability to provide CMS with electronic data and
reports necessary for effective validation and assessment of the
organization's survey process.
++ Determine the adequacy of CHAP's staff and other resources.
++ Confirm CHAP's ability to provide adequate funding for
performing required surveys.
[[Page 60471]]
++ Confirm CHAP's policies with respect to surveys being
unannounced.
++ Review CHAP's policies and procedures to avoid conflicts of
interest, including the appearance of conflicts of interest, involving
individuals who conduct surveys or participate in accreditation
decisions.
++ Obtain CHAP's agreement to provide CMS with a copy of the most
current accreditation survey together with any other information
related to the survey as we may require, including corrective action
plans.
The April 27, 2020 proposed notice also solicited public comments
regarding whether CHAP's requirements met or exceeded the Medicare CfCs
for home infusion therapy. No comments were received in response to our
proposed notice.
IV. Provisions of the Final Notice
A. Differences Between CHAP's Standards and Requirements for
Accreditation and Medicare Conditions and Survey Requirements
We compared CHAP's HIT accreditation requirements and survey
process with the Medicare CfCs of part 486, subpart I and the survey
and certification process requirements of part 488, subpart L. Our
review and evaluation of CHAP's HIT application, which was conducted as
described in section III. of this final notice, yielded the following
areas where, as of the date of this notice, CHAP has completed revising
its standards and certification processes in order to meet the
condition at:
Section 486.520(b), to address the requirement of the plan
of care must be established by a physician prescribing the type, amount
and duration for home infusion therapy.
Section 486.525(a), to include the required language
``plan of care''.
Section 488.1010(a)(6)(iv), to revise CHAP's procedures
for survey reviews.
B. Term of Approval
As authorized under Sec. 488.1040(a), we reserve the right to
conduct onsite observations of accrediting organization operations at
any time as part of the ongoing review and continuing oversight of an
accrediting organization's performance. Based on the review and
observations described in section III. of this final notice, we have
determined that CHAP's requirements for HIT meet or exceed our
requirements. Therefore, we approve CHAP as a national accreditation
organization for HITs that request participation in the Medicare
program, effective September 25, 2020 through September 25, 2024.
V. Collection of Information Requirements
This document does not impose information collection and
requirements, that is, reporting, recordkeeping or third party
disclosure requirements. Consequently, there is no need for review by
the Office of Management and Budget under the authority of the
Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35).
The Administrator of the Centers for Medicare & Medicaid Services
(CMS), Seema Verma, having reviewed and approved this document,
authorizes Lynette Wilson, who is the Federal Register Liaison, to
electronically sign this document for purposes of publication in the
Federal Register.
Dated: September 21, 2020.
Lynette Wilson,
Federal Register Liaison, Centers for Medicare & Medicaid.
[FR Doc. 2020-21147 Filed 9-24-20; 8:45 am]
BILLING CODE 4120-01-P